InxMed Announces First Patient Dosed in Phase 2 Pivotal Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer ...Middle East

NANJING, China, Sept. 7, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates to developing innovative therapies targeting drug resistance and metastasis for hard-to-treat solid tumors, today announced the dosing of the first patient in its Phase 2...

Hence then, the article about inxmed announces first patient dosed in phase 2 pivotal study of in10018 in patients with platinum resistant recurrent ovarian cancer was published today ( Thursday 08/09/2022 - 03:33 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( InxMed Announces First Patient Dosed in Phase 2 Pivotal Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer )

Also on site :

• This All-Suite Orlando Resort Is the Stress-Free Alternative to Theme Park Hotels and Here’s Why
• Sean Penn Gifted a Metal Oscar Statue After Missing the Award Show
• Ex-Belgian diplomat faces trial over Lumumba assassination